Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Triflupromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 11/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 1.00 |
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | GMNN | O75496 | 4/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.98 |
| ▸ | HTR1A | P08908 | 7/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.98 |
| ▸ | DRD1 | P21728 | 6/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triflupromazine SCHEMBL29419087 | 1.00 | LMNA (1.00) | LMNAMAPTTP53NPSR1TDP1 | |
| Triflupromazine SCHEMBL30903901 | 1.00 | LMNA (1.00) | LMNAMAPTTP53NPSR1TDP1 | |
| Triflupromazine SCHEMBL32668886 | 0.99 | CYP1A2 (1.00) | LMNAMAPTTP53NPSR1TDP1 | |
| Triflupromazine SCHEMBL44085 | 0.99 | CYP1A2 (1.00) | LMNAMAPTTP53NPSR1TDP1 | |
| Triflupromazine SCHEMBL317145 | 0.96 | CYP1A2 (0.95) | LMNAMAPTTP53NPSR1TDP1 | |
| SCHEMBL7750160 | 0.94 | TP53 (0.91) | LMNAMAPTTP53NPSR1TDP1 | |
| Triflupromazine SCHEMBL28057425 | 0.92 | CYP1A2 (0.87) | LMNAMAPTTP53NPSR1TDP1 | |
| SCHEMBL7346761 | 0.91 | TP53 (0.86) | LMNAMAPTTP53NPSR1TDP1 | |
| SCHEMBL23353457 | 0.91 | TP53 (0.85) | LMNAMAPTTP53NPSR1TDP1 | |
| Triflupromazine SCHEMBL9055400 | 0.91 | TP53 (0.85) | LMNAMAPTTP53NPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 537 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102612-A1 | COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS FOR MODULATING GLUCOSE TRANSPORT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-05-16 | — | — | WO | claimed |
| US-11344506-B2 | Rapidly disintegrating oral dissolvable film | CUREX PHARMACEUTICAL MEXICO S.A.P.I. DE C.V. (MX) | 2022-05-31 | — | — | US | claimed |
| US-10821107-B2 | Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-11-03 | — | — | US | claimed |
| US-20200325543-A1 | DIAGNOSTIC METHOD | TOLREMO THERAPEUTICS AG (CH) | 2020-10-15 | — | — | US | claimed |
| EP-3233105-B1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LTD (GB) | 2020-09-30 | — | — | EP | claimed |
| EP-3714069-A1 | DIAGNOSTIC METHOD | Tolremo Therapeutics AG (CH) | 2020-09-30 | — | — | EP | claimed |
| CN-111417730-A | Diagnostic method | 托雷莫治疗股份公司 | 2020-07-14 | — | — | CN | claimed |
| US-20190321441-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | claimed |
| US-20170348383-A1 | NOVEL COMBINATION AND USE | HELPERBY THERAPEUTICS LIMITED (GB) | 2017-12-07 | — | — | US | claimed |
| EP-3233105-A1 | NOVEL COMBINATION AND USE | Helperby Therapeutics Limited (GB) | 2017-10-25 | — | — | EP | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-20040185097-A1 | Controlled release modifying complex and pharmaceutical compositions thereof | GLENMARK PHARMACEUTICALS LTD. | 2004-09-23 | — | — | US | claimed |
| WO-2004066910-A2 | CONTROLLED RELEASE MODIFYING COMPLEX AND PHARMACEUTICAL COMPOSITIONS THEREOF | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-12 | — | — | WO | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321441-A1 | NOVEL COMBINATION AND USE | TSLP, TLR5, TLR4 | DRD2 1673/4885LMNA 3822/4885MAPT 4827/4885 |
| US-20170348383-A1 | NOVEL COMBINATION AND USE | TSLP, TLR5, TLR4 | DRD2 1673/4885LMNA 3822/4885MAPT 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.